These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

494 related items for PubMed ID: 16144975

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors.
    Arias E, Alés E, Gabilan NH, Cano-Abad MF, Villarroya M, García AG, López MG.
    Neuropharmacology; 2004 Jan; 46(1):103-14. PubMed ID: 14654102
    [Abstract] [Full Text] [Related]

  • 4. Enhancement of purinergic neurotransmission by galantamine and other acetylcholinesterase inhibitors in the rat vas deferens.
    Caricati-Neto A, D'angelo LC, Reuter H, Hyppolito Jurkiewicz N, Garcia AG, Jurkiewicz A.
    Eur J Pharmacol; 2004 Oct 25; 503(1-3):191-201. PubMed ID: 15496314
    [Abstract] [Full Text] [Related]

  • 5. Additive protective effects of donepezil and nicotine against salsolinol-induced cytotoxicity in SH-SY5Y cells.
    Das JR, Tizabi Y.
    Neurotox Res; 2009 Oct 25; 16(3):194-204. PubMed ID: 19526284
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cellular responses to nicotinic receptor activation are decreased after prolonged exposure to galantamine in human neuroblastoma cells.
    Barik J, Dajas-Bailador F, Wonnacott S.
    Br J Pharmacol; 2005 Aug 25; 145(8):1084-92. PubMed ID: 15937519
    [Abstract] [Full Text] [Related]

  • 8. Mechanisms of neuroprotective effects of nicotine and acetylcholinesterase inhibitors: role of alpha4 and alpha7 receptors in neuroprotection.
    Akaike A, Takada-Takatori Y, Kume T, Izumi Y.
    J Mol Neurosci; 2010 Jan 25; 40(1-2):211-6. PubMed ID: 19714494
    [Abstract] [Full Text] [Related]

  • 9. [Development of therapies for Alzheimer's disease based on cholinergic hypothesis-status quo and future directions].
    Shimohama S.
    Rinsho Shinkeigaku; 2013 Jan 25; 53(11):1036-8. PubMed ID: 24291871
    [Abstract] [Full Text] [Related]

  • 10. [Mechanisms of neuroprotective effects of therapeutic acetylcholinesterase inhibitors used in treatment of Alzheimer's disease].
    Takatori Y.
    Yakugaku Zasshi; 2006 Aug 25; 126(8):607-16. PubMed ID: 16880719
    [Abstract] [Full Text] [Related]

  • 11. Liraglutide prevents beta-amyloid-induced neurotoxicity in SH-SY5Y cells via a PI3K-dependent signaling pathway.
    Liu XY, Wang LX, Chen Z, Liu LB.
    Neurol Res; 2016 Apr 25; 38(4):313-9. PubMed ID: 27108910
    [Abstract] [Full Text] [Related]

  • 12. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.
    Nordberg A, Darreh-Shori T, Peskind E, Soininen H, Mousavi M, Eagle G, Lane R.
    Curr Alzheimer Res; 2009 Feb 25; 6(1):4-14. PubMed ID: 19199870
    [Abstract] [Full Text] [Related]

  • 13. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J.
    Drugs Aging; 2004 Feb 25; 21(7):453-78. PubMed ID: 15132713
    [Abstract] [Full Text] [Related]

  • 14. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
    Jann MW, Shirley KL, Small GW.
    Clin Pharmacokinet; 2002 Feb 25; 41(10):719-39. PubMed ID: 12162759
    [Abstract] [Full Text] [Related]

  • 15. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
    Noetzli M, Eap CB.
    Clin Pharmacokinet; 2013 Apr 25; 52(4):225-41. PubMed ID: 23408070
    [Abstract] [Full Text] [Related]

  • 16. Roles of nicotinic receptors in acetylcholinesterase inhibitor-induced neuroprotection and nicotinic receptor up-regulation.
    Takada-Takatori Y, Kume T, Izumi Y, Ohgi Y, Niidome T, Fujii T, Sugimoto H, Akaike A.
    Biol Pharm Bull; 2009 Mar 25; 32(3):318-24. PubMed ID: 19252271
    [Abstract] [Full Text] [Related]

  • 17. Neuroprotection by donepezil against glutamate excitotoxicity involves stimulation of alpha7 nicotinic receptors and internalization of NMDA receptors.
    Shen H, Kihara T, Hongo H, Wu X, Kem WR, Shimohama S, Akaike A, Niidome T, Sugimoto H.
    Br J Pharmacol; 2010 Sep 25; 161(1):127-39. PubMed ID: 20718745
    [Abstract] [Full Text] [Related]

  • 18. Galantamine and donepezil differently affect isolation rearing-induced deficits of prepulse inhibition in mice.
    Koda K, Ago Y, Kawasaki T, Hashimoto H, Baba A, Matsuda T.
    Psychopharmacology (Berl); 2008 Feb 25; 196(2):293-301. PubMed ID: 17912499
    [Abstract] [Full Text] [Related]

  • 19. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons.
    Takada Y, Yonezawa A, Kume T, Katsuki H, Kaneko S, Sugimoto H, Akaike A.
    J Pharmacol Exp Ther; 2003 Aug 25; 306(2):772-7. PubMed ID: 12734391
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological manipulation of the vasoconstrictive effects of amyloid-beta peptides by donepezil and rivastigmine.
    Doganay G, Khodr B, Georgiou G, Khalil Z.
    Curr Alzheimer Res; 2006 Apr 25; 3(2):137-45. PubMed ID: 16611014
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.